Cargando…

Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA

HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahajan, Supriya D., Aalinkeel, Ravikumar, Reynolds, Jessica L., Nair, Bindukumar, Sykes, Donald E., Law, Wing-Cheung, Ding, Hong, Bergey, Earl J., Prasad, Paras N., Schwartz, Stanley A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108557/
https://www.ncbi.nlm.nih.gov/pubmed/21660279
http://dx.doi.org/10.4061/2011/719139
_version_ 1782205328561012736
author Mahajan, Supriya D.
Aalinkeel, Ravikumar
Reynolds, Jessica L.
Nair, Bindukumar
Sykes, Donald E.
Law, Wing-Cheung
Ding, Hong
Bergey, Earl J.
Prasad, Paras N.
Schwartz, Stanley A.
author_facet Mahajan, Supriya D.
Aalinkeel, Ravikumar
Reynolds, Jessica L.
Nair, Bindukumar
Sykes, Donald E.
Law, Wing-Cheung
Ding, Hong
Bergey, Earl J.
Prasad, Paras N.
Schwartz, Stanley A.
author_sort Mahajan, Supriya D.
collection PubMed
description HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact in the field of HIV-1 therapeutics, and nanoparticles such as quantum rods (QRs) can be easily functionalized to incorporate siRNA forming stable nanoplexes that can be used for gene silencing. We evaluated the efficacy of the QR-si510 HIV-1 siRNA nanoplex in suppressing viral replication in the HIV-1-infected monocytic cell line THP-1 by measuring p24 antigen levels and gene expression levels of HIV-1 LTR. Our results suggest that the QR-si510 HIV-1 siRNA nanoplex is not only effective in delivering siRNA, but also in suppressing HIV-1 viral replication for a longer time period. HIV-1 nanotherapeutics can thus enhance systemic bioavailability and offer multifunctionality.
format Online
Article
Text
id pubmed-3108557
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-31085572011-06-09 Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA Mahajan, Supriya D. Aalinkeel, Ravikumar Reynolds, Jessica L. Nair, Bindukumar Sykes, Donald E. Law, Wing-Cheung Ding, Hong Bergey, Earl J. Prasad, Paras N. Schwartz, Stanley A. Patholog Res Int Research Article HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact in the field of HIV-1 therapeutics, and nanoparticles such as quantum rods (QRs) can be easily functionalized to incorporate siRNA forming stable nanoplexes that can be used for gene silencing. We evaluated the efficacy of the QR-si510 HIV-1 siRNA nanoplex in suppressing viral replication in the HIV-1-infected monocytic cell line THP-1 by measuring p24 antigen levels and gene expression levels of HIV-1 LTR. Our results suggest that the QR-si510 HIV-1 siRNA nanoplex is not only effective in delivering siRNA, but also in suppressing HIV-1 viral replication for a longer time period. HIV-1 nanotherapeutics can thus enhance systemic bioavailability and offer multifunctionality. SAGE-Hindawi Access to Research 2011-05-10 /pmc/articles/PMC3108557/ /pubmed/21660279 http://dx.doi.org/10.4061/2011/719139 Text en Copyright © 2011 Supriya D. Mahajan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mahajan, Supriya D.
Aalinkeel, Ravikumar
Reynolds, Jessica L.
Nair, Bindukumar
Sykes, Donald E.
Law, Wing-Cheung
Ding, Hong
Bergey, Earl J.
Prasad, Paras N.
Schwartz, Stanley A.
Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
title Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
title_full Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
title_fullStr Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
title_full_unstemmed Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
title_short Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
title_sort nanotherapeutics using an hiv-1 poly a and transactivator of the hiv-1 ltr-(tar-) specific sirna
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108557/
https://www.ncbi.nlm.nih.gov/pubmed/21660279
http://dx.doi.org/10.4061/2011/719139
work_keys_str_mv AT mahajansupriyad nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT aalinkeelravikumar nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT reynoldsjessical nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT nairbindukumar nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT sykesdonalde nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT lawwingcheung nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT dinghong nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT bergeyearlj nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT prasadparasn nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna
AT schwartzstanleya nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna